IDH1 and acute myeloid leukemia: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-controlled study of AG-120 in combination with azacitidine in subjects ≥ 18 Years of age with previously untreated acute myeloid leukemia with an IDH1 mutation